Logo
x

Search category

Subscribe Now

BMS

BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant Opdivo (nivolumab) + CT for Resectable Non-Small Cell Lung Cancer

BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant Opdivo (nivolumab) + CT for Resectable Non-Small Cell Lung Cancer

  • September 22, 2023
BMS to Present P-II Study Results of BMS-986278 for Progressive Pulmonary Fibrosis at ERS 2023

BMS to Present P-II Study Results of BMS-986278 for Progressive Pulmonary Fibrosis at ERS 2023

  • September 11, 2023
BMS’ Camzyos (mavacamten) Receives NICE Recommendation for adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

BMS’ Camzyos (mavacamten) Receives NICE Recommendation for adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

  • September 7, 2023
BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy

BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopa...

  • August 29, 2023
BMS’ Reblozyl (luspatercept-aamt) Receives the US FDA’s Approval as 1L Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes

BMS’ Reblozyl (luspatercept-aamt) Receives the US FDA’s Approval as 1L Treatment of Anemia in Adults with Lower-Risk Myelodysplast...

  • August 29, 2023
BMS’ Opdivo (nivolumab) Receives EC’s Approval as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma

BMS’ Opdivo (nivolumab) Receives EC’s Approval as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma

  • August 23, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.